IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Entry into a Material Definitive Agreement

IRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

to that certain indenture dated as of June15, 2015, between Ironwood Pharmaceuticals,Inc. (“Ironwood”) and U.S. Bank National Association, as trustee (the “Trustee”) (the “Indenture”),Ironwood previously issued $335.7 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2022 (the “Notes”).

On April5, 2019,Ironwood and the Trustee entered into a Supplemental Indenture to the Indenture (the “Supplemental Indenture”). to Section10.01(h)of the Indenture, the Supplemental Indenture amends the term “Valuation Period” under the Indenture to reference a ten consecutive trading day period, rather than a five consecutive trading day period, in order to conform the definition of “Valuation Period” in the Indenture to the definition of “Valuation Period” used in the preliminary offering memorandum, dated June8, 2015, relating to the offering and sale of the Notes.

The foregoing description of the Supplemental Indenture is qualified in its entirety by reference to the Supplemental Indenture, which is filed as Exhibit4.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 1.01 Financial Statements and Exhibits.


EX-4.1 2 a19-7996_1ex4d1.htm EX-4.1 Exhibit 4.1   SUPPLEMENTAL INDENTURE   Supplemental Indenture (this “Supplemental Indenture”),…
To view the full exhibit click here


Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

An ad to help with our costs